Cloprostenol (Estrumate)

Cloprostenol, marketed under the brand name Estrumate among others, is a synthetic prostaglandin F2α analog widely used in equine reproductive medicine for inducing luteolysis and controlling the estrous cycle in mares. As one of the most important medications in the equine reproductive veterinarian's toolkit, cloprostenol enables precise manipulation of the mare's reproductive cycle for breeding management, treatment of reproductive pathology, and resolution of unwanted pregnancies when medically indicated. The medication's ability to cause rapid regression of the corpus luteum and subsequent return to estrus makes it invaluable for modern breeding programs requiring predictable timing of ovulation and breeding.

The mechanism of action of cloprostenol involves binding to prostaglandin F receptors on luteal cells, initiating a cascade of events leading to luteolysis or destruction of the corpus luteum. The corpus luteum is responsible for progesterone production that maintains diestrus and early pregnancy, so its regression results in rapid decline of progesterone levels. This progesterone withdrawal triggers return to estrus within two to five days in most mares, as the hypothalamic-pituitary-ovarian axis resumes normal cyclic function. Cloprostenol is effective only when a functional corpus luteum is present, typically between days 5 and 16 of the estrous cycle. Administration during estrus or early diestrus before corpus luteum maturation produces no effect.

Cloprostenol is available as a sterile injectable solution for intramuscular administration. The standard concentration allows for accurate dosing based on the established protocol for equine patients. Being a synthetic analog rather than natural prostaglandin, cloprostenol offers advantages including greater stability, more predictable pharmacokinetics, and reduced intensity of some side effects compared to natural prostaglandin preparations. A single injection is typically sufficient for luteolysis in mares, though some protocols involve repeat administration. The injectable route requires proper technique and appropriate injection site selection for optimal results and minimal injection site reactions.

The safety profile of cloprostenol in horses is well-characterized, with transient side effects being common but typically mild and self-limiting. Sweating, increased respiratory rate, and mild abdominal discomfort are frequently observed following administration and usually resolve within an hour. More significant concerns relate to accidental human exposure, particularly for pregnant women or those with respiratory conditions, as prostaglandins can induce bronchospasm and potentially affect human pregnancy. Veterinary supervision is essential for appropriate patient selection, proper administration technique, and management of any adverse effects that may occur.

The primary indication for cloprostenol in equine medicine is induction of luteolysis to bring mares into estrus for breeding purposes. Mares in diestrus, the phase of the cycle dominated by the corpus luteum and elevated progesterone, will not exhibit estrus behavior or ovulate without intervention. When breeding timing needs to be coordinated with stallion availability, mare owner schedules, or embryo transfer programs, cloprostenol administration allows precise timing of estrus onset. Within two to five days following injection, most mares will show behavioral estrus and develop a preovulatory follicle, enabling planned breeding. This capability is fundamental to efficient management of modern breeding operations.

Estrus synchronization protocols in breeding programs commonly utilize cloprostenol to coordinate groups of mares for timed breeding or embryo collection and transfer procedures. By administering cloprostenol to mares in diestrus, reproductive managers can bring multiple mares into estrus simultaneously, optimizing the use of valuable stallion time and veterinary resources. Various synchronization protocols exist, some combining cloprostenol with other hormonal agents such as GnRH analogs or progestins to achieve more precise ovulation timing. These protocols are particularly valuable for large breeding operations, embryo transfer programs, and situations where fresh cooled or frozen semen with limited availability must be used efficiently.

Treatment of pyometra, a serious uterine infection characterized by accumulation of purulent material in the uterus with a persistent corpus luteum maintaining cervical closure, represents an important therapeutic application of cloprostenol. The prostaglandin induces luteolysis and subsequent cervical relaxation, allowing drainage of infected material from the uterus. This treatment is typically combined with uterine lavage and appropriate antimicrobial therapy. Resolution of pyometra is essential for mare health and future fertility, and cloprostenol-induced luteolysis is often the first step in successful treatment protocols.

Pregnancy termination, when medically indicated, can be accomplished using cloprostenol in early to mid-pregnancy. Situations requiring pregnancy termination may include twins detected after acceptable treatment windows, mares inadvertently bred when pregnancy is contraindicated, or mares with health conditions making pregnancy continuation unsafe. Cloprostenol causes luteolysis and progesterone withdrawal, leading to pregnancy loss when administered before the placenta assumes progesterone production around day 100-120 of gestation. Later pregnancy termination requires different approaches, and all pregnancy termination should be performed under veterinary guidance with appropriate follow-up care.

Selection of cloprostenol among available prostaglandin products often relates to practitioner experience and preference, product availability, and specific protocol requirements. Cloprostenol offers advantages including synthetic stability and relatively moderate side effect intensity compared to some natural prostaglandin preparations. The single-injection efficacy for luteolysis is well-established, and predictable timing of estrus onset facilitates breeding management. Cost considerations, individual mare response history, and integration with other reproductive management strategies influence product selection. Veterinary expertise guides appropriate use based on specific clinical situations and breeding program goals.

Dosing protocols for cloprostenol in horses follow established guidelines with the standard dose being 250 micrograms administered intramuscularly as a single injection. This dose is effective for luteolysis in mares when a mature corpus luteum is present. The medication is supplied in multi-dose vials at concentrations allowing accurate measurement of the required volume. Veterinary administration is standard practice, as proper patient selection, timing relative to the estrous cycle, and injection technique significantly influence treatment outcomes. The relatively narrow therapeutic window regarding cycle timing makes veterinary expertise essential for optimal results.

Typical dosing involves a single intramuscular injection of 250 micrograms (typically 1 mL of standard formulations) regardless of mare size. Unlike many equine medications that require weight-based dosing adjustments, cloprostenol dosing is relatively standardized across the range of horse sizes. Both ponies and draft horses typically receive the same dose, though some practitioners may slightly adjust for extreme sizes. The rationale for standardized dosing relates to the mechanism of action at the level of the corpus luteum rather than body-wide distribution. Veterinary judgment determines any dose modifications based on individual circumstances.

Treatment protocols vary based on the indication. For simple estrus induction, a single injection is typically sufficient, with estrus expected within two to five days. Synchronization protocols may involve single or multiple injections according to the specific protocol being followed, sometimes combined with other reproductive hormones for enhanced precision. For pyometra treatment, cloprostenol administration initiates therapy, with follow-up treatments and uterine lavage continuing as indicated by response. Pregnancy termination protocols may involve single or repeated administration depending on gestational age and response, with veterinary monitoring essential throughout.

Administration technique involves standard intramuscular injection practices. The neck muscles provide the most common injection site, with proper needle selection (typically 18-20 gauge, 1.5-inch needle) and aseptic technique. The gluteal muscles offer an alternative site, though caution is warranted regarding proper depth and avoiding sensitive structures. Subcutaneous administration is not recommended, as absorption characteristics differ from the established intramuscular route. Proper restraint ensures handler and mare safety during administration. Documentation of injection site, time, and any immediate reactions supports good medical record keeping.

Missed doses or timing considerations differ from chronic medication protocols, as cloprostenol is typically used as a single-injection intervention rather than ongoing therapy. If a planned injection is delayed, administration can proceed when circumstances allow, though optimal synchronization timing may be affected. In multi-injection protocols, timing of subsequent doses should be discussed with the veterinarian if the initial dose timing changes. Since effectiveness depends on corpus luteum presence and maturity, injections given too early in the cycle (before day 5 post-ovulation) will be ineffective and may need repeating at appropriate timing.

Post-administration expectations include onset of estrus within two to five days for mares in mid-diestrus. Mares should be teased or examined daily following administration to detect estrus onset for breeding timing. Veterinary examination to monitor follicular development helps predict ovulation timing. If estrus does not occur within the expected timeframe, the mare should be evaluated to determine whether the corpus luteum was appropriate age at injection or whether other factors prevented expected response. Follow-up protocols depend on the specific situation and breeding program requirements.

General tolerability of cloprostenol in horses includes expected transient effects related to the pharmacological action of prostaglandins on smooth muscle throughout the body. Most mares experience some degree of immediate post-injection effects, which are considered normal responses rather than adverse reactions. These effects typically resolve within 30 to 60 minutes without intervention. The predictability of these responses allows proper preparation and monitoring. Compared to natural prostaglandin preparations, synthetic analogs like cloprostenol tend to produce somewhat milder systemic effects while maintaining equivalent luteolytic efficacy.

Common side effects occur in the majority of treated mares and include sweating, which may range from mild dampening to profuse sweating depending on individual sensitivity. Increased respiratory rate and mild respiratory distress are frequently observed, reflecting prostaglandin effects on bronchial smooth muscle. Mild colic signs including pawing, looking at flanks, and transient restlessness result from prostaglandin-induced smooth muscle contraction in the gastrointestinal tract. Increased intestinal motility may cause loose manure or increased frequency of defecation. These effects typically peak within 15-30 minutes post-injection and resolve by one hour. Providing a quiet environment and observation during this period is appropriate standard practice.

Moderate side effects, while less common, include more pronounced respiratory distress or more severe colic-like symptoms that persist beyond the typical one-hour window. Some mares may lie down or roll due to abdominal discomfort, requiring monitoring to prevent self-injury. Elevated heart rate beyond that expected from mild distress may occur. Injection site reactions including swelling, pain, or subsequent abscess formation can occur with any intramuscular injection but are not unique to cloprostenol. Veterinary attention should be sought if moderate side effects persist beyond one to two hours, if the mare appears severely distressed, or if injection site reactions develop.

Serious adverse effects from cloprostenol are uncommon but can occur. Severe bronchospasm, though rare, could be life-threatening in mares with pre-existing respiratory compromise. Severe colic requiring medical intervention has been reported occasionally. Anaphylactic reactions are possible with any injectable medication. Cardiovascular effects beyond expected mild changes could indicate concerning reactions. Mares with cardiac conditions may be at increased risk for adverse cardiovascular responses. Any signs of severe respiratory distress, cardiovascular collapse, or colic not resolving within expected timeframes warrant immediate veterinary attention and appropriate supportive care.

Rare effects and important safety considerations include the potential for inadvertent pregnancy termination if a mare is unknowingly pregnant when treated. Pregnancy status should be confirmed before administering cloprostenol when pregnancy is not the intended outcome. Human safety concerns are significant, as prostaglandins can cause bronchospasm in sensitive individuals and may affect human pregnancy. Pregnant women should not handle cloprostenol, and all handlers should avoid skin contact and self-injection. Accidental human exposure, particularly to the eyes or through injection, requires immediate medical attention. Safe handling protocols protect all personnel involved in cloprostenol administration.

Known hypersensitivity to cloprostenol or other prostaglandin compounds represents an absolute contraindication. While true allergy to prostaglandins is uncommon, any mare that has shown severe adverse reactions to previous prostaglandin administration should not receive cloprostenol without careful risk-benefit assessment and appropriate precautions. Cross-reactivity between different prostaglandin preparations is expected, so sensitivity to one prostaglandin product should be considered a contraindication to all similar products. Documentation of previous adverse reactions helps inform future treatment decisions and alerts veterinarians to potential issues.

Respiratory disease represents a significant contraindication due to prostaglandin effects on bronchial smooth muscle. Mares with heaves (recurrent airway obstruction), inflammatory airway disease, or other conditions compromising respiratory function may experience severe bronchospasm following cloprostenol administration. The baseline respiratory compromise limits the mare's ability to compensate for additional bronchoconstrictive effects. If prostaglandin administration is necessary in a mare with respiratory disease, careful risk assessment, availability of bronchodilator medications, and close monitoring are essential. Alternative approaches to reproductive management may be preferable in mares with significant respiratory compromise.

Cardiovascular disease creates concern regarding cloprostenol use due to potential effects on heart rate and blood pressure. Mares with significant cardiac conditions may be unable to tolerate the hemodynamic effects of prostaglandin administration. Evaluation of cardiovascular status is advisable before administering cloprostenol to mares with known or suspected heart disease. The stress of immediate post-injection effects could be detrimental to mares with compromised cardiovascular function. Veterinary assessment helps determine whether prostaglandin use is appropriate or whether alternative approaches should be pursued.

Reproductive and life stage contraindications are critically important. Administration to pregnant mares will cause abortion unless pregnancy termination is the specific intended outcome, so pregnancy status must be known before treatment. Mares with active uterine infections, while potentially candidates for cloprostenol as part of pyometra treatment, require comprehensive evaluation and combined therapy rather than prostaglandin alone. Mares with gastrointestinal compromise, including active colic or recent gastrointestinal surgery, should not receive prostaglandins due to effects on intestinal motility. Current health status and any concurrent medications should be communicated to the veterinarian to identify potential contraindications specific to individual mares.

Major drug interactions with cloprostenol center on concurrent use of other medications affecting the reproductive axis or medications that might potentiate prostaglandin effects. Concurrent administration with oxytocin could produce additive effects on smooth muscle contraction, potentially increasing severity of gastrointestinal and uterine effects. Non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the effectiveness of prostaglandins through inhibition of prostaglandin synthesis pathways, though the clinical significance in the context of exogenous prostaglandin administration varies. Timing of NSAID administration relative to cloprostenol should be considered, with some practitioners avoiding concurrent use while others find it does not significantly impact luteolytic efficacy.

Moderate interactions include effects on the efficacy of progestin therapy. Cloprostenol administration to mares receiving progestins such as altrenogest will induce luteolysis, but the exogenous progestin may partially overcome some expected responses. If a mare on progestin therapy requires prostaglandin treatment, the interaction between these opposing hormonal influences should be considered in treatment planning. Similarly, combining prostaglandins with other reproductive hormones in synchronization protocols requires understanding of how these agents interact to achieve desired outcomes. Veterinary expertise guides appropriate protocol design.

Minor interactions and practical considerations include the timing of administration relative to other medications. While specific drug-drug interactions with common equine medications are not extensively documented, general principles suggest avoiding unnecessary concurrent medications when administering agents with significant systemic effects. Sedatives or analgesics used to manage post-injection discomfort should be selected and dosed appropriately, recognizing that the mare may already be experiencing cardiovascular effects from the prostaglandin. Documentation of all medications received helps identify any unexpected interactions that might occur.

Competition and regulatory considerations for cloprostenol relate to its classification as a prohibited substance under most equine competition rules. The medication is not intended for use in competition horses outside of legitimate reproductive management conducted well before competitive events. Detection times extend beyond the immediate treatment period, though specific withdrawal time guidance varies by regulatory organization. For breeding mares that may return to competition, sufficient time must elapse between cloprostenol treatment and competition to ensure compliance with drug rules. Consultation with a veterinarian familiar with relevant competition regulations helps determine appropriate timing when reproductive management must be coordinated with competition schedules.

Monitoring requirements following cloprostenol administration focus on the immediate post-injection period and subsequent reproductive response. Mares should be observed for at least 30-60 minutes following injection to monitor for expected transient effects and identify any concerning reactions requiring intervention. Parameters to observe include respiratory rate and effort, signs of abdominal discomfort, sweating intensity, and overall demeanor. Most mares can be returned to normal housing after the immediate post-injection period passes. Subsequent monitoring involves teasing or veterinary examination to detect estrus onset and track reproductive response to treatment.

Special population considerations include adjustments for mares with underlying health conditions. Geriatric mares may have reduced cardiovascular or respiratory reserve, warranting closer monitoring and potentially dose adjustment consideration. Mares with history of severe previous reactions should be identified and managed with extra caution if prostaglandin treatment is necessary. Debilitated mares may experience more pronounced effects from the stress of prostaglandin-induced smooth muscle contraction. Individual mare history and current health status should inform treatment decisions and monitoring intensity.

Competition and performance horse considerations are significant due to drug rule implications. Cloprostenol is a prohibited substance under FEI, USEF, and most racing jurisdiction rules. While reproductive management of breeding mares may legitimately require prostaglandin use, timing relative to any planned competition must ensure complete clearance before testing. Detection times can extend for days to weeks depending on the sensitivity of testing methods. Maintaining documentation of all reproductive treatments protects owners and trainers in case of any questions about competition compliance.

Administration precautions for handlers are critically important due to prostaglandin effects on human physiology. Pregnant women must never handle cloprostenol due to risk of inducing abortion. Individuals with asthma or other respiratory conditions may experience severe bronchospasm from skin exposure or inhalation. Accidental self-injection could cause severe effects requiring emergency medical treatment. Gloves should be worn during handling, and immediate washing is necessary if skin contact occurs. Needles should be handled carefully to prevent accidental injection. Safety data sheets should be available and reviewed by all personnel handling the product.

Long-term considerations relate primarily to the cumulative effects of repeated prostaglandin administration over a mare's breeding career rather than continuous use. Occasional use for reproductive management is not associated with adverse long-term effects. However, mares requiring frequent prostaglandin treatments may warrant evaluation for underlying reproductive issues affecting normal cyclicity. Documentation of all reproductive treatments over time provides valuable information for ongoing breeding management and veterinary assessment.

Storage requirements for cloprostenol follow manufacturer guidelines, typically specifying storage at controlled room temperature between 15-25°C (59-77°F) protected from light. The aqueous injectable solution should not be frozen. Multi-dose vials should be stored with attention to maintaining sterility of remaining contents, using aseptic technique when withdrawing doses. Most products have defined beyond-use dating once vials are broached, typically 28 days for multi-dose vials when stored appropriately. Storing medication in original packaging protects from light exposure. Barn or clinic storage areas should provide reasonably stable temperatures, with refrigeration required only if specified by manufacturer guidelines.

Handling and safety precautions are paramount for cloprostenol due to significant human health risks. Prostaglandins can be absorbed through skin contact, making glove use essential during handling. Pregnant women must not handle the product under any circumstances due to risk of abortion. Individuals with asthma or respiratory conditions are at risk for severe bronchospasm. All handlers should be trained on safe handling procedures and informed of risks. Wearing safety glasses during preparation and administration protects against accidental eye exposure. If skin contact occurs, immediate washing with soap and water is required. Accidental self-injection constitutes a medical emergency requiring immediate treatment. Keeping emergency contact information accessible supports rapid response to any exposure incidents.

Expiration and disposal guidelines must be carefully followed. Expired products should not be used, as efficacy may be reduced and safety could be compromised. Disposal of unused or expired cloprostenol should follow guidelines for pharmaceutical waste, with many veterinary clinics having established protocols for prostaglandin disposal. Empty vials and used syringes should be disposed of in appropriate sharps containers. Local regulations may specify requirements for prostaglandin disposal. Never dispose of prostaglandin products in regular trash or down drains. Maintaining inventory awareness prevents accumulation of expired product requiring disposal and ensures fresh stock is available when needed.

Draft breeds receiving cloprostenol typically respond similarly to light horse breeds, with standard dosing protocols generally applicable. The larger body mass of draft horses does not necessitate dose adjustment for luteolytic efficacy, as the mechanism of action involves local effects on the corpus luteum rather than body-wide distribution requirements. Draft mares may potentially tolerate the transient systemic effects with less apparent distress due to their generally calm temperaments, though individual variation exists. Belgian, Percheron, Clydesdale, Shire, and other draft breeds used in breeding programs benefit from the same precise cycle management capabilities that cloprostenol provides to light horse breeding operations.

Light horse breeds and warmbloods represent the majority of mares receiving cloprostenol in breeding programs. Thoroughbred and Standardbred operations heavily utilize prostaglandin protocols for breeding management. Warmblood breeding programs producing sport horses for dressage, jumping, and eventing employ cloprostenol in synchronization and breeding timing protocols. Quarter Horses, Paints, and Appaloosas in stock horse breeding programs similarly benefit. Arabian breeding programs use cloprostenol for cycle management. Response to prostaglandin administration is generally consistent across these breeds when appropriate timing relative to corpus luteum maturity is observed.

Ponies and miniature horses respond to cloprostenol similarly to larger horses, with standard doses typically effective for luteolysis. The smaller body size does not require dose reduction for the luteolytic effect, though some practitioners may observe that smaller equines experience more pronounced transient systemic effects relative to their size. Welsh, Shetland, Miniature Horse, and other pony breeds undergoing reproductive management receive the same dose as larger horses. Miniature horse breeding operations, where precise timing can be particularly important given the challenges of breeding very small equines, benefit from prostaglandin-based cycle control.

Breed-specific sensitivities to prostaglandins have not been clearly documented, and cloprostenol is used across all horse breeds without known breed-specific contraindications. Individual variation in the intensity of transient post-injection effects exists within all breeds rather than between breeds. Mares of any breed with respiratory compromise require special consideration regardless of breed. Arabian horses, which may have higher prevalence of certain respiratory conditions, should be evaluated individually. Friesians with any cardiovascular concerns warrant careful assessment. Overall, breed does not significantly influence cloprostenol use decisions, with individual mare factors being more relevant to safe and effective treatment.

Same class alternatives to cloprostenol include other prostaglandin F2α preparations used in equine reproductive medicine. Dinoprost tromethamine (Lutalyse) is a natural prostaglandin F2α preparation that offers equivalent luteolytic efficacy. Dinoprost may produce somewhat more intense transient side effects compared to synthetic analogs in some mares. Fenprostalene is another synthetic prostaglandin analog with similar applications. Selection between prostaglandin products often relates to veterinary preference, availability, cost, and individual mare response history. All prostaglandin preparations share the same fundamental mechanism and contraindications, with differences primarily in formulation and side effect intensity.

Different class options for achieving reproductive management goals depend on the specific objective. For maintaining mares out of estrus, progestin therapy with altrenogest provides an alternative approach that suppresses rather than induces estrus. For inducing ovulation in mares already in estrus, GnRH analogs such as deslorelin provide options that do not require a corpus luteum to be effective. Human chorionic gonadotropin (hCG) similarly induces ovulation in estrous mares. For treatment of uterine infections, antimicrobial therapy may be combined with or in some cases substitute for prostaglandin therapy depending on the specific situation. Alternative approaches are selected based on the mare's cycle status and treatment goals.

Complementary therapies and guidance for mares receiving prostaglandin treatment typically involve comprehensive reproductive management protocols. Follicular monitoring via ultrasound examination helps optimize breeding timing following prostaglandin-induced luteolysis. Uterine treatments including lavage may be indicated for mares with uterine pathology. Breeding management strategies are coordinated with the expected estrus onset. Record keeping documenting treatment timing and reproductive responses informs future management decisions. Veterinary expertise is essential for designing protocols appropriate to individual mares and breeding program goals. Never administer prostaglandins without veterinary guidance, as inappropriate timing or patient selection can compromise outcomes and mare safety.